Loading...

AMLX AMYLYX PHARMACEUTICALS INC Company Mergers 8-K Filing

MYLY

MLX

AMYLYX PHARMACEUTICALS INC

(AMLX)

2026 8-K

Corporate Presentation Update

Financial Results

New Drug Candidate

Financial Results Update

Stock Offering Announcement

Program Discontinuation

Financial Statements

Financial Statements

Financial Results

Collaboration Announcement

Financial Results

Clinical Trial Results

Financial Results Announcement

Acquisition of Avexitide Asset

Asset Purchase Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Management Change

Financial Results Announcement

Financial Results Announcement

Conference Call

Rejection of Marketing Auth...

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Conference Presentation

External Links:

On March 24, 2026, Amylyx Pharmaceuticals announced updates in their corporate presentation, highlighting the completion of enrollment in the Phase 3 LUCIDITY trial and the Phase 1 LUMINA trial, and additional analysis from the Phase 2 PREVENT study.

AI Assistant

AMYLYX PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.